Study: MDMA-Assisted Psychotherapy Will Be Cost-Effective in the Treatment of PTSD

MDMA-assisted psychotherapy is projected to be a cost-effective treatment for severe and treatment-resistant PTSD. Economic analysis indicates that treating one thousand patients with this intervention could save the healthcare system approximately 103 million dollars over 30 years and significantly improve patient outcomes measured in quality-adjusted life years. This analysis is based on data from six phase two trials which included patients with prior suicide attempts. Research demonstrates higher treatment response rates compared to current PTSD standard-of-care medications. Further clinical trials will investigate long-term durability of these results and optimization of the treatment protocol.